Aim The aim of this study was to assess the combined use of the radiotracers 18
F-NaF in treatment response evaluation of a group of multiple myeloma (MM) patients undergoing high-dose chemotherapy (HDT) followed by autologous stem cell transplantation (ASCT) by means of static (whole-body) and dynamic PET/CT (dPET/CT). Patients and methods Thirty-four patients with primary, previously untreated MM scheduled for treatment with HDT followed by ASCTwere enrolled in the study. All patients underwent PET/ CT scanning with 18 F-FDG and 18 F-NaF before and after therapy. Treatment response by means of PET/CT was assessed according to the European Organization for Research and Treatment of Cancer (EORTC) 1999 criteria. The evaluation of dPET/CT studies was based on qualitative evaluation, semiquantitative (SUV) calculation, and quantitative analysis based on two-tissue compartment modelling and a non-compartmental approach leading to the extraction of fractal dimension (FD). Results An analysis was possible in 29 patients: three with clinical complete response (CR) and 26 with non-CR (13 patients near complete response-nCR, four patients very good partial response-VGPR, nine patients partial response-PR). After treatment, 18 F-FDG PET/CT was negative in 14/29 patients and positive in 15/29 patients, showing a sensitivity of 57.5 % and a specificity of 100 %. According to the EORTC 1999 criteria, F-NaF PET/CT, 4/29 patients (13.8 %) had a negative baseline scan, thus failed to depict MM. Regarding the patients for which a direct lesion-to-lesion comparison was feasible, 18 F-NaF PET/ CT depicted 56 of the 129 18 F-FDG positive lesions (43 %). Follow-up 18 F-NaF PET/CT showed persistence of 81.5 % of the baseline 18 F-NaF positive MM lesions after treatment, despite the fact that 64.7 % of them had turned to 18 F-FDG negative. Treatment response according to 18 F-NaF PET/CT revealed CR in one patient ( F-NaF PET/CT studies showed that SUV average , SUV max , as well as the kinetic parameters K 1 , influx and FD from reference bone marrow and skeleton responded to therapy with a significant decrease (p < 0.001). Conclusion F-FDG PET/CT demonstrated a sensitivity of 57.7 % and a specificity of 100 % in treatment response evaluation of MM. Despite its limited sensitivity, the performance of 18 F-FDG PET/CT was satisfactory, given that 6/9 false negative patients in follow-up scans (66.7 %) were clinically characterized as nCR, a disease stage with very low tumor mass. On the other hand, 18 F-
Introduction
High-dose chemotherapy (HDT) with melphalan followed by autologous stem cell transplantation (ASCT) is the standard of care for multiple myeloma (MM) patients aged 65 years or younger [1] [2] [3] [4] [5] . Recently, the incorporation of novel agents (thalidomide, lenalidomide, bortezomib) into induction regiments and maintenance therapy of MM has improved the quality of treatment response, which in turn has led to extended progression free survival (PFS) and overall survival (OS) rates [4, 6, 7] . This previously unreported, prolonged survival of MM patients renders accurate assessment of response to therapy a necessity. Treatment response evaluation in MM is based on well-defined laboratory parameters and, in cases of a complete serological response, the assessment of plasma cell percentage in bone marrow, usually acquired from the iliac crest [8, 9] . 18 F-FDG PET/CT is a sensitive functional imaging modality. The updated International Myeloma Working Group (IMWG) criteria consider patients with focal skeletal lesions and increased uptake with underlying osteolytic destruction in one of the new imaging modalities as indicative of active myeloma [10, 11] . Although its routine application in the follow-up of MM is not yet recommended, 18 F-FDG PET/ CT appears to be useful in the monitoring of MM and has been proposed to strengthen the evaluation of the quality of treatment response [12] [13] [14] [15] [16] . 18 F-NaF is a PET tracer used for skeletal imaging, which accumulates in both osteoblastic and osteolytic lesions, reflecting regional blood flow and bone remodeling [17] [18] [19] [20] . 18 F-NaF PET/CT is evolving as an important imaging method for the assessment of malignant bone diseases [21] [22] [23] . Despite being suggested as a potential valuable tool in the assessment of MM [24] [25] [26] [27] [28] , three recently published prospective studies have yielded rather discouraging results regarding the performance of 18 F-NaF PET/CT in evaluation of myeloma bone disease [29] [30] [31] . Nevertheless, the data regarding application of 18 F-NaF PET/CT in MM are still considered to be limited.
The aim of this prospective study was to assess the combined use of the radiotracers 18 F-FDG and 18 F-NaF in treatment response evaluation of a group of MM patients undergoing HDT followed by ASCT by means of static (wholebody) and dynamic PET/CT (dPET/CT).
Materials and methods

Patients
The evaluation included initially 34 patients confirmed to suffer from MM based on the criteria established by the IMWG, at the time point of patient recruitment, and scheduled for treatment with HDT followed by ASCT [32] . All patients had primary disease and had never received chemotherapy. Their mean age was 59.1 years (range 38-73 years). Table 1 presents analytically the characteristics of the patients investigated. Patients with a negative baseline 18 F-FDG PET/CT were excluded from the statistical analysis in order to avoid bias in the interpretation of the results (n = 5 patients). Patient data on PFS and OS up to July 2016 (time of writing) are also presented. The analysis was conducted in accordance to the declaration of Helsinki with approval of the ethical committee of the University of Heidelberg and the federal agency of radiation protection.
PET/CT data acquisition
All patients underwent PET/CT scanning with 18 F-FDG and 18 F-NaF before and after therapy with HDT and ASCT. The mean time between baseline and follow-up study was 95 days (range 47-228 days) ( Table 1 ). The double tracer study in each patient was completed in two consecutive days. For reasons of radiation protection the patients were intravenously administered with a maximum dosage of 250 MBq F-NaF (range 167-247 MBq) on the second day. Data acquisition consisted of two parts for each tracer: the dynamic part (dPET/CT studies of the lower lumbar spine and the pelvic skeleton) and the static part (whole body PET/CT). Details regarding data acquisition are described in a previous publication of our group [29] .
PET/CT data analysis
Data analysis was based on: visual (qualitative) analysis, semi-quantitative evaluation based on SUV calculations, and quantitative analysis of the 18 F-FDG and 18 F-NaF PET/CT scans, performed before (baseline PET/CT) and after (follow-up PET/CT) treatment.
Qualitative analysis was based on visual assessment of the PET/CT scans, according to criteria applied in previous studies from our group [29, 33] . Briefly, bone marrow/skeletal foci presenting with significantly enhanced 18 F-FDG uptake, for which another benign aetiology was excluded, were considered indicative for myeloma. Afterwards, the results of 18 F-NaF PET/CT were correlated to those of 18 F-FDG PET/CT, which served as reference. The basic concept regarding 18 F-NaF PET/CT evaluation was that only lesions that correlated with respective lesions on 18 F-FDG PET/CT were considered as MM-indicative [29] .
Semi-quantitative evaluation was based on volumes of interest (VOIs) and on subsequent calculation of SUVs. VOIs were drawn with an isocontour mode (pseudo-snake) and were placed over sites of MM involvement, as well as over FNaF PET/CT data, derived from reference tissue of the pelvis, was performed using a dedicated software and based on a twotissue compartment model, with methods already reported in literature and performed previously from our group [29, [34] [35] [36] [37] [38] [39] [40] . The application of a two-tissue compartment model leads to the extraction of the kinetic parameters K 1 , k 2 , k 3 and k 4 , as well as influx (Ki) that describe specific molecular processes for each tracer. In the case of 18 F-FDG, K 1 reflects the carrier-mediated transport of 18 F-FDG from plasma to tissue while k 2 reflects the transport of the radiopharmaceutical back from tissue to plasma, and k 3 represents the phosphorylation rate while k 4 the dephosphorylation rate of the glucose analogue. Influx (K i ) is derived from the equation = (K 1 x k 3 )/ (k 2 + k 3 ). In case of 18 F-NaF, rate constants K 1 and k 2 describe the fluoride ions exchange with hydroxyl groups of hydroxyapatite crystal of the bone and the reverse, while k 3 and k 4 represent the formation of fluoroapatite and the opposite [25] . Influx (K i ) is related to Ca 2+ influx and bone apposition rate and, presumably, represents bone remodelling rate [41] .
In addition to performing compartment analysis, a noncompartment model based on the fractal dimension (FD) for the time-activity data was also applied. FD is a parameter of heterogeneity based on the box counting procedure of chaos theory and was calculated for the time activity data in each individual voxel of a VOI. The values of FD vary from 0 to 2 showing the more deterministic or chaotic distribution of the tracer activity via time in a VOI [42] .
Treatment response evaluation by laboratory and imaging
Treatment response evaluation was performed according to the clinical gold standard, based on the European Bone Marrow Transplantation Criteria, introduced by Bladé et al. [8] and modified by the IMWG uniform response criteria for multiple myeloma [9] . These criteria served as reference standard in our study.
Treatment response by means of 18 F-FDG PET/CT was assessed according to the European Organization for Research and Treatment of Cancer (EORTC) 1999 criteria leading to four groups of therapy response (complete response, 18 F-FDG PET/CT CR; partial response, 18 F-FDG PET/CT PR; stable disease, 18 F-FDG PET/CT SD; progressive disease, 18 F-FDG PET/CT PD) [43] . Because of lack of defined treatment monitoring criteria based on 18 F-NaF PET/ CT, we also applied the EORTC 1999 criteria for this tracer.
Moreover, quantitative data derived from dynamic PET/CT studies from the pelvis were also applied in treatment response evaluation. In particular, the kinetic parameters retrieved from application of two-tissue compartment modelling, as well as FD in reference bone marrow or skeleton were compared before and after therapy.
Statistical analysis
Data were statistically evaluated using the STATA/SE 12.1 (StataCorp) software on an Intel Core (2 · 3.06 GHz, 4 GB RAM) running with Mac OS X 10.8.4 (Apple Inc., Cupertino, CA, USA). The statistical evaluation was performed using the descriptive statistics and Wilcoxon ranksum test. Moreover, we calculated the sensitivity and specificity of 18 F-FDG PET/CT for determination of remission status based on the clinical gold standard [8, 9] . The results were considered significant for p less than 0.001 (p < 0.001).
Results
Treatment response evaluation based on the clinical gold standard
Patient population characteristics, as well as the results of treatment response evaluation are reported in Table 1 . All patients showed at least partial clinical response after completion of HDT and ASCT. Five MM patients had a negative baseline 18 F-FDG PET/CT scan and were, therefore, excluded from the statistical analysis. These five patients were also MM-negative on 18 F-NaF PET/CT. Regarding the remaining 29 patients, three demonstrated complete response (CR) and 26 demonstrated non-CR. In particular, 13 patients showed near complete response (nCR), four patients very good partial response (VGPR), and nine patients showed partial response (PR) according to the clinical evaluation criteria. In five patients the number of lesions was too large to be exactly calculated (more than 20 lesions). Two patients demonstrated an intense diffuse pattern of bone marrow uptake without focal lesions. No baseline EMD was detected. After treatment, 18 F-FDG PET/CT became negative in 14 patients, while it remained positive in 15 patients. In correlation with the clinical gold standard, 18 F-FDG PET/CT after therapy was true positive in 15/26 patients with non-CR, and false negative in 11/26 patients with non-CR, resulting in a sensitivity of 57.7 %. On the other hand, 18 F-FDG PET/CT was true negative in 3/3 patients with CR, resulting in a specificity of 100 %. Table 2) (Figs. 1, 2, and 3) . 
Survival data
The data on PFS and OS up to July 2016 (time of writing) are presented in Table 1 . The follow-up time ranged from 15 to 52 months. Only one patient had died. Twelve patients demonstrated progression, while 18 patients were progressionfree. One patient was lost to follow-up. Because of lack of late follow-up data for all patients, we did not proceed to survival analysis in order to compare the survival rates between the different groups.
Kinetic analysis data
The results of dPET/CT evaluations from reference tissue before and after therapy are presented in Tables 3 and 4 . In terms of both 18 F-FDG dPET/CT and 18 F-NaF dPET/CT, the patients responded to therapy with a statistically significant decrease of the semi-quantitative parameters SUV average and SUV max , as well as of the quantitative parameters K 1 , influx (K i ) and FD (p < 0.001 respectively). The changes in the respective TACs for both tracers are presented in Figs. 5 and 6.
Discussion
Assessment of treatment response in MM is based on certain, well-defined laboratory parameters [8, 9] . Nevertheless, novel imaging modalities such as PET/CT are nowadays considered valuable tools in improving the definition of response to therapy especially in case of complete response where the percentage of plasma cells in the bone marrow is assessed only from a single location at the iliac crest. Several studies have highlighted the potency of 18 F-FDG PET/CT in accurate response evaluation to therapy in MM [16, [44] [45] [46] while the role of 18 F-NaF PET/CT in the evaluation of myeloma lesions is still being investigated. In the present prospective study we assessed the combined use of 18 F-FDG PET/CT and 18 F-NaF PET/CT in treatment response evaluation of MM patients undergoing HDT with melphalan followed by ASCT.
In patient-based analysis 18 F-FDG PET/CT showed a sensitivity of 57.7 %, a result similar to results previously reported by Derlin et al. who found sensitivities of 54.6 % and 50.0 % for correct determination of remission status after stem F-NaF PET criteria applied in our study PR cell transplantation using also the same clinical criteria as gold standard [14, 46] . A possible explanation for this relatively limited sensitivity is that MM cells have a rather low proliferation rate and some lesions might be too small to be depicted, given that six of the false negative patients (66.7 %) were clinically characterized as nCR, a disease stage with very low tumour mass [14, 47] 18 F-FDG PET/CT negative patients [12, 13] . Moreover, the Zamagni group has proven that the achievement of conventional CR and 18 F-FDG PET/CT negativity ensured a significantly prolonged progression free survival (PFS) and an extended overall survival (OS) compared to the achievement of conventional CR but with persistence of 18 F-FDG avidity after therapy [16] . The specificity of 18 F-FDG PET/CT was 100 % with 3/3 patients clinically characterized as CR being 18 F-FDG negative. 18 F-FDG PET/CT is considered a relatively specific imaging modality regarding MM response assessment, due to its ability to differentiate between active disease and fibrotic lesions [15, 45] . As expected, a direct comparison of the treatment response assessed (Fig. 3) , the lesion demonstrated a persistence of the F-FDG PET/CT was not feasible.
The performance of 18 F-NaF PET/CT was rather limited. In patient-based analysis, baseline 18 F-NaF PET/CT was negative in 13.8 % of the F-FDG uptake is expected to be seen with a loss of viable cancer cells, which is in the case in patients with partial or complete response [48] . On the other hand, 18 F-NaF uptake mechanism corresponds to osteoblastic activity. The accumulation of 18 F-NaF in osteolytic lesions, as in case of MM, takes place in the accompanying, even minimal, reactive osteoblastic changes [19] .
To date there is little information available about the role of 18 F-NaF PET in treatment monitoring of systemic cancer therapy. Hillner et al. have recently assessed the impact of 18 FNaF PET results in a set of 2,217 oncological patients receiving systemic therapy. Their results showed a high impact of the modality in patients with progressive osseous metastatic disease, with a 40 % change in treatment plan after 18 F-NaF PET [21] . The authors stressed, however, the non-tumor specific nature of the tracer as an indicator of reactive bone formation in response to various insults and the limitation of being subject to the flare phenomenon associated with systemic therapy.
The experience from 99m Tc-MDP bone scintigraphy (BS), the analogue of 18 F-NaF PET for conventional nuclear medicine, is much larger. Although the response to treatment is evident through a decrease in 99m Tc-MDP uptake in BS, several studies have shown that an increased activity of the boneseeking tracer in the area of a tumour lesion may persist for several months after therapy, partly in terms of the healing, osteoblastic, reactive process, [49] [50] [51] [52] [53] Tc-MDP BS. Clinical followup, serial tumor markers and radiological findings confirmed the 18 F-FDG PET findings, leading to the conclusion that some of the BS results should be interpreted as representing a persistent bone reaction, not active metastatic disease [54] . This previous experience with bone matrix radiotracers was the reason that the sensitivity and specificity of 18 F-NaF PET/ CT were not assessed with regard to the clinical gold standard.
Apart from the conventional evaluation of whole-body PET/ CT scans, we performed quantitative assessment of the dynamic PET/CT data derived from reference bone marrow ( 18 F-FDG), and reference skeleton ( 18 F-NaF) of the pelvis after application of two-tissue compartment modelling. The quantitative aspect is a major advantage of PET, which is neglected when using whole-body protocols and visual/qualitative evaluation as the only diagnostic tool. Only limited data exist on quantitative assessment of tracer kinetics in MM. Our group has recently shown that the 18 F-FDG kinetic parameters K 1 , influx (K i ), as well as SUV from reference bone marrow of the os ilium, correlated significantly with bone marrow malignant plasma cell infiltration rate [39] . The herein presented results revealed that in the case of 18 F-FDG, tracer uptake (reflected by SUV average and SUV max ), its transport capacity (K 1 ), and its influx rate (K i ) responded to HDT and ASCT with a significant decrease. These findings are in agreement with previous findings from Dimitrakopoulou-Strauss et al., who studied a group of MM patients undergoing anthracyclinebased chemotherapy with dynamic 18 F-FDG PET/CT prior to the onset of therapy and after the first cycle. The authors found a significant decrease (p < 0.000) of SUV, FD, V B , and influx (K i ) for 18 F-FDG as derived from reference bone marrow of the os ilium, in response to treatment [55] . The herein presented results provide more evidence in the direction of establishment of 18 F-FDG PET/CT as a tool for treatment response evaluation in MM; we proved that in a group of patients that clinically responded to therapy with at least PR, certain parameters involved in 18 F-FDG metabolism also responded with a significant decrease of their values. Considering that the particular 18 F-FDG parameters correlate with the bone marrow malignant plasma cell infiltration rate, an indicator of myeloma burden and one of the myeloma defining events [10] , our data stress the F-NaF-associated kinetic parameters demonstrated similar changes as 18 F-FDG in response to therapy. In particular, 18 F-NaF uptake (SUV average and SUV max ), the rate of fluoride ions exchange with hydroxyl groups of hydroxyapatite crystal of the bone (K 1 ), Ca 2+ influx, bone apposition rate, and, presumably, bone remodelling rate (K i ) decreased significantly after HDT and ASCT. Myelomatous bone disease after ASCT is little understood [56] . The fact that bone marrow transplantation may affect the skeleton has been demonstrated by Gandhi et al. in an heterogeneous group of oncological patients, one of whom had MM. The authors showed that 3 months after ASCT there was a significant decline of bone mineral density in the femoral neck and a non-significant trend towards reduction in the lumbar spine [57] . Terpos et al. have shown that bone formation markers do not normalise until the eighth month post-ASCT, providing an indication that bone formation may delay in normalising [58] . Further, in one of the few published treatment monitoring studies by means of dynamic 18 F-NaF PET, Installé et al. have demonstrated in 14 patients with Paget's disease receiving bisphosphonates therapy that SUV max , K 1 , and influx constant K i decreased significantly as response to treatment [59] . F-FDG concentration during the 60 min of dynamic PET acquisition in reference bone marrow before (upper row) and after therapy with HDT and ASCT (lower row). The curves are derived from bone marrow of the os ilium that served as reference (blue curve with green dots) and from the common iliac artery (curve with gold dots). Small decrease in the radiotracer concentration in reference tissue VOIs after therapy. The corresponding kinetic parameters responded to therapy also with a decrease To the best of our knowledge, these are the first data regarding bone turnover changes in MM patients receiving HDT and ASCT, evaluated by means of dynamic PET/CT.
In addition to two-tissue compartment modelling for tracer kinetics assessment, we also applied a non-compartmental approach based on the box counting procedure of the chaos theory for the analysis of dPET data, resulting in another index representative of tissue heterogeneity, fractal dimension (FD) [42] . Fractal geometry has found use in pathology for assessment of irregularities [60] . Our group has shown that FD of 18 F-FDG correlates significantly with the degree of bone marrow malignant plasma cell infiltration rate [39] . In the present study we found that FD for both tracers decreased significantly, reflecting a decline of the heterogeneity of the concentration of both tracers over time in response to treatment, a result in accordance with the changes of compartment-derived kinetic parameters.
This study has some limitations. Firstly, the number of patients enrolled was relatively small. Therefore, further studies with a larger study population are warranted to generalize the herein presented results. Secondly, most of the PET/CT positive findings were not histopathologically confirmed. However, this is usually not possible in the clinical setting. Another limitation is the confinementof the dynamic PET/CTstudies onlyinthe anatomic area of the pelvis, since whole-body dynamic studies cannot be performed.We used a two-bed position protocolfor the dynamic PET acquisition, which allows the study of a relatively large field of F-NaF concentration during the 60 min of dynamic PET acquisition in reference skeleton before (upper row) and after therapy with HDT and ASCT (lower row). The curves are derived from osseous tissue of the os ilium that served as reference (blue curve with green dots) and from the common iliac artery (curve with gold dots). Decrease in the radiotracer concentration in reference tissue VOIs after therapy. The corresponding kinetic parameters responded to therapy also with a decrease view of 44 cm. Nevertheless, new PET/CT scanners allow dynamic studies over several bed positions by using a continuous bed movement, thus, facilitating the use of dynamic protocols and reducing the whole acquisition time. Finally, the lack of late follow-up data for all patients prevented us from proceeding to survival analysis between the different patient groups, which will be the topic of a future publication of our group.
Conclusion
In the present study 18 F-FDG PET/CT demonstrated a sensitivity of 57.7 % and a specificity of 100 % in treatment response evaluation of 29 MM patients undergoing HDT and ASCT, using the clinical response criteria as reference standard. Despite its limited sensitivity, the performance of 18 F-FDG PET/CT was satisfactory, given that 6/9 false negative patients in follow-up scans (66.7 %) were clinically characterized as nCR, a disease stage with very low tumor mass. In contrary, 18 F-NaF PET/CT did not aid significantly in treatment response evaluation of MM patients, at least in an early phase. Dynamic PET/CT studies demonstrated a decrease of SUVs and specific kinetic parameters in reference tissue for both 18 F-FDG and 18 F-NaF as response to treatment, reflecting changes in a molecular level before any morphological changes take place.
